TABLE 24Incremental cost-effectiveness ratios (cost per QALY gained)

Total costs and QALYsTRA + ANALAP + LETANALET
Total costs (£)54,748.9251,882.5323,340.8823,327.52
Total QALYs1.871.711.291.29
ICER
TRA + ANA vs LAP + LET£17,914/QALY gained
TRA + ANA vs ANA£54,151/QALY gained
TRA + ANA vs LET£54,174/QALY gained

From: 4, Assessment of cost-effectiveness

Cover of Lapatinib and Trastuzumab in Combination with an Aromatase Inhibitor for the First-Line Treatment of Metastatic Hormone Receptor-Positive Breast Cancer which Over-Expresses Human Epidermal Growth Factor 2 (HER2): A Systematic Review and Economic Analysis
Lapatinib and Trastuzumab in Combination with an Aromatase Inhibitor for the First-Line Treatment of Metastatic Hormone Receptor-Positive Breast Cancer which Over-Expresses Human Epidermal Growth Factor 2 (HER2): A Systematic Review and Economic Analysis.
Health Technology Assessment, No. 15.42.
Fleeman N, Bagust A, Boland A, et al.
Southampton (UK): NIHR Journals Library; 2011 Dec.
© 2011, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.